CFA
HUMA icon

Carroll Financial Associates’s Humacyte HUMA Stock Holding History

Carroll Financial Associates’s Portfolio HUMA Stock Details HUMA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q4 		$0 Buy
+30
New +$297 ﹤0.01% 1759

Other funds holding HUMA

YCMGA
York Capital Management Global Advisors New York $87.8M AUM 45.55% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
UOC
UBS O'Connor Chicago, Illinois $3.38B AUM 63.08% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
MIM
Monashee Investment Management Boston, Massachusetts $184M AUM 197.43% 1-Year Est. Return
DCP
Diameter Capital Partners New York $1.07B AUM 152.29% 1-Year Est. Return
Charles Schwab
Charles Schwab San Francisco, California $654B AUM 26.35% 1-Year Est. Return
GIA
Gladstone Institutional Advisory Palm Beach Gardens, Florida $2.7B AUM 23.82% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Carroll Financial Associates's HUMA Position: Q4 2021 in Review

Carroll Financial Associates opened a new position in Humacyte (HUMA) in Q4 2021: 30 shares worth $0. The stake represents ﹤0.01% of the portfolio and ranks #1759 among its holdings.

61 funds tracked by Wall St. Rank hold HUMA as of Q4 2021.

  • Carroll Financial Associates held 30 shares of Humacyte worth $0 as of Q4 2021.
  • Humacyte was a new Carroll Financial Associates position in Q4 2021.
  • Humacyte made up ﹤0.01% of Carroll Financial Associates's portfolio in Q4 2021, its #1759 holding.
  • 61 funds tracked by Wall St. Rank held Humacyte as of Q4 2021.

Based on Carroll Financial Associates's 13F filing for Q4 2021, filed 6 Jan 2022.